Catalog No.
DHG01303
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
NAALAD1, Prostate-specific membrane antigen, NAALADase I, PSMA, PSM, Pteroylpoly-gamma-glutamate carboxypeptidase, Glutamate carboxypeptidase 2, N-acetylated-alpha-linked acidic dipeptidase I, Glutamate carboxypeptidase II, FOLH1, FGCP, FOLH, Folylpoly-gamma-glutamate carboxypeptidase, Folate hydrolase 1, GCPII, Membrane glutamate carboxypeptidase, Cell growth-inhibiting gene 27 protein, mGCP
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q04609
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
7E11-C5.3 radiolabelled, Indium In1111 ProstaScint, capromab pendetide, CAS: 145464-28-4
Clone ID
Capromab
Capromab Pendetide imaging of prostate cancer, PMID: 10803318
111 In-Capromab pendetide, PMID: 20641439
Capromab pendetide. A review of its use as an imaging agent in prostate cancer, PMID: 9571393
Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer, PMID: 11272670
Indium-111 capromab pendetide in the management of recurrent prostate cancer, PMID: 18279057
Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer, PMID: 23595605
Update on fused capromab pendetide imaging of prostate cancer, PMID: 15882479
Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution, PMID: 24718894
Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT, PMID: 21493787
Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer, PMID: 10604708
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy, PMID: 11920467
Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer, PMID: 21892036
Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer, PMID: 17293236
Evaluation of alternative methods for radiochemical purity testing of indium-111 capromab pendetide, PMID: 21555286
Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging, PMID: 21477947
The role of (111)In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer, PMID: 12114876
Indium-111-capromab pendetide scans: an important test relevant to clinical decision making, PMID: 11248605
Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy, PMID: 12721246
Current Clinical Applications of the In-capromab Pendetide Scan (ProstaScint(R) Scan, Cyt-356), PMID: 16985714
Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial, PMID: 24144687
111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer, PMID: 20189846
Prostate-specific membrane antigen-based imaging, PMID: 22658884
Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer, PMID: 18164863
Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer, PMID: 20961696
Editorial comment, PMID: 19616227
In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT, PMID: 20008977
111In-capromab pendetide: the evolution of prostate specific membrane antigen and the nuclear imaging of its 111In-labelled murine antibody in the evaluation of prostate cancer, PMID: 18034550
Technology insight: monoclonal antibody imaging of prostate cancer, PMID: 16607370
A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy, PMID: 10850293
Prostate cancer abdominal metastases detected with indium-111 capromab pendetide, PMID: 9544673
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland, PMID: 19616259
Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm, PMID: 18163941
Detection of Recurrent Non-Hodgkin Lymphoma on In-111 Capromab Pendetide Imaging, PMID: 25899589
Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure, PMID: 18343445
123 I-Labeled (S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedoic acid, PMID: 20641935
Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer, PMID: 9790041
Indium-111 Capromab Pendetide (ProstaScint(®)) Demonstrates Renal Cell Carcinoma and Aortocaval Nodal Metastases from Prostate Adenocarcinoma, PMID: 26420994
Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy, PMID: 19843189
123 I-Labeled (S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl) ureido)pentyl)ureido)pentanedoic acid, PMID: 20641856
Imaging of prostate cancer, PMID: 17157630
111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group, PMID: 9598514
Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer, PMID: 27679869
Therapy with immunoglobulin: applications for monoclonal antibodies, PMID: 16878853
Capromab Pendetide immunoscintigraphy: connecting the dots for prostate cancer imaging, PMID: 10803317
Disposable bioreactors: maturation into pharmaceutical glycoprotein manufacturing, PMID: 19517075
Technical considerations for acquiring and processing indium-111 capromab pendetide images, PMID: 9291068
ProstaScint and its role in the diagnosis of prostate cancer, PMID: 17620043
Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate, PMID: 20434196
Progress in SPECT/CT imaging of prostate cancer, PMID: 16866563
Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide, PMID: 17284381
For research use only. Not for human or drug use.
